Connexion
E-mail
Mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse

Eli Lilly and Company: Lilly Announces Voluntary Delisting from Euronext Paris

03/10/2019 | 15:35
share with twitter
share with LinkedIn
share with facebook

Eli Lilly and Company
Eli Lilly and Company: Lilly Announces Voluntary Delisting from Euronext Paris

03-Oct-2019 / 15:30 CET/CEST
Information réglementaire transmise par EQS Group.
Le contenu de ce communiqué est de la responsabilité de l'émetteur.


October 3, 2019

 

 

 

 

 

 

For Release:  Immediately

Refer to:   Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media)  

  Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)

        
 

Lilly Announces Voluntary Delisting from Euronext Paris
 

INDIANAPOLIS, IN - Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) ("Lilly Shares") from Euronext Paris due to the very low trading volume, costs and administrative requirements related to its secondary listing on Euronext Paris. The Board of Directors of Euronext Paris S.A. has approved this request.  

 

Following the delisting from Euronext Paris, Lilly Shares will remain listed on the New York Stock Exchange (NYSE), Lilly's primary listing exchange.

 

A voluntary sales facility procedure on the NYSE will be provided by Lilly to its shareholders holding their Lilly Shares under Euroclear France ("Euronext Shareholders") during which such Euronext Shareholders will have the following options:

  • decide not to participate in the voluntary sales facility and keep their Lilly Shares which they will be able to trade on Euronext Paris through and including the trading day prior to the delisting date and only on the NYSE thereafter; or
  • participate in the voluntary sales facility described below and sell all or part of their Lilly Shares on the NYSE.

 

Euronext Shareholders Not Participating

Euronext Shareholders who do not wish to sell their Lilly Shares under the sales facility, or otherwise have taken no action to tender their Lilly Shares in the sales facility, will be able to trade their Lilly Shares only on the NYSE following the delisting date. Any such trade will be subject to the terms applied by their financial intermediary who will take the necessary steps to move their Lilly Shares from Euroclear France to the relevant alternative central system for depositary.

 

Participating Euronext Shareholders

Euronext Shareholders who wish to sell their Lilly Shares on the NYSE under the sales facility should request their financial intermediaries to deliver their Lilly Shares from October 7, 2019 to October 18, 2019 included, to BNP Paribas Securities Services, acting as centralizing agent, pursuant to the procedure described in the applicable Euronext notice expected to be published on October 3, 2019.

 

The Lilly Shares delivered to BNP Paribas Securities Services will be sold on the NYSE beginning on October 23, 2019 by a broker, at market prices prevailing at the time of the sale.

 

BNP Paribas Securities Services will calculate the average sale price of the Lilly Shares and will be in charge of transferring the sale proceeds to the participating Euronext Shareholders.

 

Lilly will pay the fees for the centralization and the brokerage fee related to the sale on the NYSE of the Lilly Shares delivered to BNP Paribas Securities Services as part of the sales facility.

 

Euronext Shareholders are reminded that they may tender their Lilly Shares in the sales facility on a voluntary basis.

 

No guarantee can be given by Lilly or by BNP Paribas Securities Services as to the price at which the Lilly Shares will actually be sold on the NYSE. This process is being provided solely as an accommodation to Euronext Shareholders. Individual investors may determine not to participate in this process or may decide not to take any action in which case no guarantee can be given on the terms applied by their financial intermediary after the delisting. Individual investors are urged to consult their own investment advisors before making a decision to participate or not in this process.

 

The calendar of the sales facility and the delisting described above can be summarized as follows (it being specified that Lilly reserves the right to amend this calendar):

 

Sales Facility

 

Commencement of the sales facility procedure

10/07/2019

Closing of the sales facility procedure

10/18/2019

End of the centralization by BNP Paribas Securities Services

10/23/2019 (before 4 p.m. Paris time)

Sale of Lilly Shares tendered to the sales facility procedure on the NYSE

Beginning on 10/23/2019

Proceeds of sale in USD converted into Euros
 

As soon as possible after receipt of proceeds of the sale

Settlement of sale proceeds to relevant

financial institutions

As soon as possible after receipt of proceeds of the sale

 

 

Delisting

 

Last day of trading of Lilly Shares on Euronext Paris

10/30/2019

Delisting of Lilly Shares from Euronext Paris

10/31/2019

 

Euronext Shareholders participating in the sales facility procedure (i) acknowledge and agree to

assume the risks associated with changes in the market price of Lilly Shares and currency exchange rates that may occur between the time Lilly Shares are delivered to BNP Paribas Securities Services and the sale of such Lilly Shares on the NYSE, and (ii) acknowledge and accept that from the time their Lilly Shares are delivered to BNP Paribas Securities Services, they will not be entitled to any subsequent dividend declared by the board of directors of Lilly. All tender instruction of Lilly Shares under the sales facility are irrevocable.

 

Lilly Shares will be delisted from Euronext Paris on October 31, 2019.

 

Lilly Shares will continue to be listed on the NYSE under the symbol "LLY".

 

Shareholders are invited to contact their financial intermediaries for any additional information.

 

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.  F-LLY   

# # #


Fichier PDF dépôt réglementaire

Titre du document : Lilly Announces Voluntary Delisting from Euronext Paris
Document : http://n.eqs.com/c/fncls.ssp?u=VYPQBKMUPG


Langue : Français
Entreprise : Eli Lilly and Company
Lilly Corporate Center
46285 Indianapolis
États-Unis
Téléphone : +1-317-276-2000
E-mail : hern_kevin_r@lilly.com
Internet : https://www.lilly.com/
ISIN : US5324571083
Ticker Euronext : LLY
Catégorie AMF : Informations privilégiées / Autres communiqués
EQS News ID : 885091
 
Fin du communiqué EQS News-Service

885091  03-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=885091&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter
share with LinkedIn
share with facebook
Réagir à cet article
Réagir le premier
Publier
loader
Toute l'actualité sur ELI LILLY AND COMPANY
16/04Les valeurs à suivre vendredi 16 avril 2021 à Wall Street -
AO
16/04ELI LILLY  : a trouvé un cocktail plus efficace contre les variants
AO
16/04ELI LILLY  : demande de révocation d'une EUA à la FDA
CF
13/04ELI LILLY  : recrute un nouveau directeur de l'information
CF
12/04ELI LILLY  : accords d'achat modifiés avec le gouvernement US
CF
12/04ELI LILLY  : résultats encourageants pour le Retevmo
CF
08/04ELI LILLY  : résultats décevants d'une étude dans la Covid
CF
07/04ELI LILLY  : la FDA prolonge l'examen du baricitinib
CF
29/03ELI LILLY  : données positives avec GSK dans la Covid-19
CF
29/03Les valeurs à suivre aujourd'hui à Wall Stree Lundi 29 mars 2021
AO
Plus d'actualités
Recommandations des analystes sur ELI LILLY AND COMPANY
Plus de recommandations
Données financières
CA 2021 27 915 M - 23 166 M
Résultat net 2021 7 148 M - 5 932 M
Dette nette 2021 11 631 M - 9 652 M
PER 2021 24,2x
Rendement 2021 1,76%
Capitalisation 172 Mrd 172 Mrd 143 Mrd
VE / CA 2021 6,59x
VE / CA 2022 6,48x
Nbr Employés 35 000
Flottant 99,5%
Graphique ELI LILLY AND COMPANY
Durée : Période :
Eli Lilly and Company : Graphique analyse technique Eli Lilly and Company | Zone bourse
Graphique plein écran
Tendances analyse technique ELI LILLY AND COMPANY
Court TermeMoyen TermeLong Terme
TendancesBaissièreHaussièreHaussière
Evolution du Compte de Résultat
Consensus
Vente
Achat
Recommandation moyenne ACCUMULER
Nombre d'Analystes 22
Objectif de cours Moyen 215,78 $
Dernier Cours de Cloture 189,64 $
Ecart / Objectif Haut 34,5%
Ecart / Objectif Moyen 13,8%
Ecart / Objectif Bas -10,4%
Révisions de BNA
Dirigeants et Administrateurs
Nom Titre
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Secteur et Concurrence
Var. 1janvCapitalisation (M$)
ELI LILLY AND COMPANY12.32%172 381
JOHNSON & JOHNSON3.37%428 315
ROCHE HOLDING AG0.42%292 008
PFIZER, INC.4.78%217 158
NOVARTIS AG-3.24%199 551
MERCK & CO., INC.-5.06%196 581